Xyphos Biosciences
San Francisco, California, United States
About Xyphos Biosciences
Xyphos Biosciences develops a CAR-T cell therapy platform called ACCEL (Advanced Cellular Control through Engineered Ligands), for treating relapsed hematological malignancies and solid tumors. The platform enables precise control of activity and targeting of universal CAR-T cell, termed convertibleCAR-T, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Website: xyphosinc.com
- Phone: (650) 243-2951
Canonical: https://fsome.com/organization/xyphos-biosciences-2475136 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.